Carlsmed

Carlsmed Net Debt per Share

The Net Debt per Share of Carlsmed (CARL) as of Nov 17, 2026 is -0.93 USD. In the previous year, Net Debt per Share was 0.08 USD — a change of -1,282.91% (lower).

Net Debt per Share

-0.93USD

YoY

-1,282.91%

Last updated:

Net Debt per Share of Carlsmed is 2024 -0.93 USD. Net Debt per Share of Carlsmed was 2023 0.08 USD. It decreases by -1,282.91% lower compared to the previous year.

The Carlsmed Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2023
0.08 USD
Jan 1, 2024
-0.93 USD
The Carlsmed Net Debt per Share history
YEARNet Debt per ShareYoY
-0.93USD-1,282.91%
0.08USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carlsmed Stock analysis

What does Carlsmed do? Carlsmed, Inc. generates revenue through its aprevo technology platform, which provides AI-based solutions for the surgical workflow. The platform includes pre-operative AI-enabled planning software that uses diagnostic imaging and algorithms to create personalized surgical plans and design aprevo interbody implants. Intra-operative advanced visualization tools support precision placement of these implants, while post-operative data collection offers insights to refine future planning. The company targets medical professionals and hospitals in the United States, focusing on lumbar interbody fusion procedures. Its products are sold under the aprevo brand, with the platform available in the U.S. market for surgical planning and implant design. Carlsmed's revenue streams come from the commercial sale of its aprevo technology platform, which integrates pre-operative planning, intra-operative visualization, and post-operative data analytics. The platform is specifically designed for lumbar interbody fusion procedures, addressing the needs of healthcare providers seeking to enhance surgical precision and outcomes. By leveraging AI-driven tools, Carlsmed enables personalized implant design and real-world data collection to improve surgical planning processes. The company's offerings are marketed to hospitals and surgeons in the U.S. healthcare sector, emphasizing the aprevo brand's role in digital surgical planning. The aprevo technology platform serves as Carlsmed's core product, offering a comprehensive solution for surgical workflows. Its pre-operative software utilizes standard-of-care imaging and AI algorithms to develop patient-specific plans and implant designs. Intra-operative tools provide advanced visualization for precise implant placement, while post-operative data collection informs continuous improvement of the planning process. The platform is indicated for use in lumbar interbody fusion procedures and is commercially available in the United States, targeting healthcare institutions that prioritize AI-enhanced surgical planning and outcomes. Carlsmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carlsmed stock

Net Debt per Share of Carlsmed is -0.93 USD in 2024.

Net Debt per Share of Carlsmed changed from 0.08 USD to -0.93 USD, representing a -1,282.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Carlsmed since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Carlsmed

All Key Metrics — Carlsmed